FDA warned 30 telehealth companies about compounded GLP-1 ads. What patients should know before buying weight-loss drugs online

If you are shopping online for a lower-cost GLP-1 weight-loss drug, the FDA’s latest actions are a reason to slow down and verify what you are being sold.

On March 3, 2026, the FDA said it sent warning letters to 30 telehealth companies over false or misleading marketing of compounded GLP-1 products. On April 1, 2026, the agency followed with a policy clarification explaining that compounding is not banned outright, but it is allowed only under specific conditions. For patients, the main takeaway is simple: a compounded GLP-1 product is not the same thing as an FDA-approved medicine, and it is not the same category as an FDA-approved generic drug.

That does not mean every compounded product is unlawful or unsafe. It does mean patients should be more careful than they might realize when a website promises a cheaper, easier, or “same as brand” option.

Why this is in the news now

The FDA says some of the telehealth marketing crossed an important line. According to the agency, some websites suggested compounded GLP-1 products were the same as approved drugs or failed to make clear who was actually compounding the medicine. That matters because the source of the drug, how it is made, and how it is labeled are central safety questions.

The timing also matters. National GLP-1 supply problems that helped drive demand for compounded versions have been easing. As supply stabilizes, the legal room for large-scale copycat compounding becomes narrower. The April 1 FDA clarification was meant to explain what may still qualify for compounding exemptions and what may be considered an essentially copied product.

For patients and families, this is less about corporate disputes and more about a basic safety issue: when you buy a drug online, you need to know exactly what it is, who prescribed it, who filled it, and how it should be used.

What compounded GLP-1 drugs are, and what they are not

A compounded drug is a medication prepared by a pharmacy or outsourcing facility for a specific need, such as a patient who cannot use a standard product because of an allergy, a dosing issue, or another documented clinical reason.

That is different from an FDA-approved drug. Approved drugs go through FDA review for safety, effectiveness, manufacturing, labeling, and quality controls before marketing. Compounded drugs do not go through that same premarket review.

It is also different from a generic drug. A generic drug is an FDA-approved version of a brand-name drug that must meet specific standards. Compounded GLP-1 products are not FDA-approved generics.

This distinction can sound technical, but it has real consequences. If an online ad makes a compounded product sound interchangeable with an approved product, patients may assume the FDA has reviewed it in the same way. The FDA says that assumption can be misleading.

Why regulators are worried about online GLP-1 sales

The FDA’s March action focused on two main concerns.

Some marketing implied compounded products were the same as FDA-approved GLP-1 drugs.
Some marketing made it hard for patients to tell who actually compounded the medication.

Those may sound like advertising details, but they affect how people judge risk. If a patient believes a telehealth brand itself is making the drug, or assumes the product is basically an approved medicine in different packaging, that patient may not ask the right questions about pharmacy licensing, ingredients, storage, or dose.

High costs and insurance gaps help explain why so many people look online in the first place. For some patients, compounded offers may seem like the only affordable route. But lower price does not erase the need for verification. In fact, it can make verification more important.

Safety problems the FDA has already flagged

The FDA has described several concerns with unapproved GLP-1 drugs used for weight loss, including compounded products sold online.

Dosing errors

Some patients have received products that required them to measure doses themselves from a vial and syringe. The FDA has said it received reports of patients taking incorrect doses and reports that some clinicians may also have miscalculated doses. The agency has also flagged reports tied to dosing schedules that went beyond the approved-label approach, such as larger doses, more frequent dosing, or faster dose increases.

When that happens, people may develop side effects that are hard to manage, including nausea, vomiting, diarrhea, abdominal pain, and constipation.

Shipping and refrigeration problems

Injectable GLP-1 products may need refrigeration. The FDA says it has received complaints about compounded GLP-1 shipments arriving warm or with inadequate ice packs. If a product needs cold storage and arrives warm, quality may be affected.

That means shipping is not just a convenience issue. It is a drug-quality issue.

Fraudulent labels and counterfeit products

The FDA advises patients to look closely at labels for warning signs such as spelling errors, bad addresses, or pharmacy information that does not seem right. The agency has also warned about counterfeit or illegally marketed GLP-1 products. In some cases, the drug may contain the wrong ingredient, too much or too little active ingredient, or no active ingredient at all.

That risk increases when products are sold through unofficial channels, including websites or social media offers that do not clearly identify a licensed pharmacy.

Semaglutide salt forms

The FDA has separately warned about semaglutide salt forms, such as semaglutide sodium and semaglutide acetate. These are different active ingredients from the semaglutide used in approved drugs. The agency has said it does not have information showing these salts have the same chemical and pharmacologic properties as the ingredient in approved products, and it is not aware of a lawful basis for their use in compounding.

Adverse-event reports do not tell the whole story

The FDA has received hundreds of adverse-event reports involving compounded semaglutide and tirzepatide products. But those numbers need context. The agency says underreporting is likely because many state-licensed pharmacies are not required to send reports to FDA, and it also says it cannot always tell whether the drug directly caused every reported harm. In other words, the reports are a warning sign, not a clean head-to-head measure of risk.

What the evidence still does not show

A recent journal-indexed paper looked at compounded semaglutide and tirzepatide products being offered online and found wide variation in formulation. Some products combined these drugs with other ingredients. Others used forms such as sublingual preparations or orally disintegrating tablets. The authors concluded that safety and effectiveness for many of these unique formulations remain largely unknown.

That is an important point for patients. The evidence gap is not just about whether a product works. It is also about whether the exact version being sold online has been studied in a meaningful way. This paper was not a clinical trial comparing outcomes in patients, so it does not prove one product is worse than another. But it does reinforce the central concern: some compounded products differ enough from approved medicines that people should not assume they behave the same way.

When compounding may still be appropriate

The FDA’s April 1 clarification did not say that all compounding of GLP-1 drugs is illegal.

Under current policy, compounding may still qualify for exemptions in specific situations. For example, under section 503A, a drug generally must be compounded for an individual patient based on a prescription. If the compounded drug would otherwise be considered essentially a copy of a commercially available product, the prescriber must determine and document that the compounded version will make a significant difference for that identified patient.

In plain language, that means legitimate compounding may still have a role when there is a real patient-specific medical reason. It is not supposed to be a broad shortcut for mass online marketing of lookalike products.

Questions to ask before ordering a GLP-1 online

If you are considering an online offer, ask these questions before you pay:

Who is the licensed prescriber? You should know the name and credentials of the clinician evaluating you.
Which state-licensed pharmacy is filling the prescription? Do not settle for a vague company name.
Does the label match the pharmacy that supposedly filled it? If something looks off, call the pharmacy directly.
What exactly is in the product? Ask for the exact active ingredient, strength, and formulation.
Does it require refrigeration? If so, ask how it will be shipped and what to do if it arrives warm.
How is the dose measured? Ask for instructions in clear units such as milligrams or milliliters, not just vague syringe markings.
What is the titration schedule? You should know how and when the dose is supposed to increase.
Who can answer questions after delivery? A pharmacist or clinician should be reachable if you are unsure how to use it.

If a seller cannot answer those questions clearly, that is a warning sign.

When to call a clinician right away

Contact a clinician or pharmacist promptly if you receive an online GLP-1 product and:

you are unsure how much to inject or how to measure the dose,
the product arrives warm when it appears to require refrigeration,
the label seems mismatched, misspelled, or otherwise suspicious,
you develop severe nausea, vomiting, diarrhea, abdominal pain, or constipation,
you have signs of dehydration such as dizziness, weakness, fainting, or inability to keep fluids down,
you develop a severe injection-site reaction or another concerning new symptom.

If the problem appears urgent, seek urgent care or emergency care. If a product seems counterfeit, mislabeled, or causes a serious reaction, patients and clinicians can report the issue to FDA MedWatch.

What this means for readers

The FDA’s March warning letters were not a recall of approved GLP-1 medicines. They were a warning about how some compounded products were being marketed online.

For everyday buyers, the safest takeaway is this: compounded GLP-1 drugs may still have a legitimate, limited role, but they should not be treated as automatically equivalent to FDA-approved products. A lower online price may come with extra uncertainty about the source, the formulation, the shipping conditions, and the dose.

Before ordering, verify the prescriber, the pharmacy, the label, the refrigeration plan, and the dosing instructions. If anything feels unclear, stop and ask questions before using the product.

Sources

This article is for general informational purposes only and is not medical advice. Research findings can be early, limited, or subject to change as new evidence emerges. For personal guidance, diagnosis, or treatment, consult a licensed clinician. For current outbreak or public health guidance, follow your local health department, the CDC, or another relevant public health authority.